Tarik Möröy, Ph.D., FCAHS is Director of the Hematopoiesis & Cancer research unit and Full Research Professor at the Montreal Clinical Research Institute/Institut de recherches cliniques de Montréal (IRCM) since 2006. He holds the Canada Research Chair (Tier 1) in Hematopoiesis and Immune Cell Differentiation since 2007 and is also Full Research Professor at the Université de Montréal and Adjunct Professor at McGill University. Dr. Möröy was the President and Scientific Director of the IRCM from March 2006 until February 2019. His research focuses on the role and function of transcription factors in hematopoiesis and immune cell differentiation. He co-discovered the transcription factors and epigenetic regulators Gfi1 and Gfi1b over 20 years ago and he and his group were able to demonstrate the implication of these factors in the innate and acquired immune response, the differentiation and activation of lymphoid cells, the function and dendritic cells, macrophages and more recently in the generation of platelets and functional megakaryocytes. The Moroy lab also discovered a variant allele of Gfi1 and Gfi1 expression levels of are associated with human AML and more recently found new functions of Gfi1 and Gfi1b in DNA repair, the Wnt/beta catenin signaling and the regulation of p53 by post-translational modifications. Since 2003, the group has also have been interested in the c-Myc co-factor and BTB/POZ domain protein Miz-1 and could show its role in lymphoid differentiation and in acute lymphoblastic leukemia.
As the IRCM’s President and Scientific Director, he provided leadership for 35 principal investigators with research and/or clinical expertise in the fields of cancer, cardiovascular and respiratory disease, neurobiology, immunology, medicinal chemistry and ethics. He is responsible for strategic planning; researcher recruitment (14 new researchers were recruited since 2007); the institute’s funding; university, hospital and government relations; Master’s, doctorate and post-doctorate training; public communications and education; operations of the IRCM clinic; and overseeing the budget of one of Canada’s leading biomedical research institutions. Under his management, the IRCM vastly expanded its technical core facilities services (genomics, proteomics, and bioinformatics) and created a graduate program focused on translational research in order to bridge the gap between basic laboratory research and the needs of the clinical practice, thus accelerating the shift towards personalized medicine. These initiatives centred around the desire to “provide passionate researchers with the ideal conditions to experiment with their boldest ideas, test their theories and pave their own way for the benefit of us all.”
Dr. Möröy has authored more than 300 publications, including 173 original articles and reviews in specialized journals, as well as over 150 contributions to scientific meetings. In 2014, he received a recognition award from the Leukemia and Lymphoma Society. He was also appointed “Honorary Guest Professor” by the Capital University in Beijing for his outstanding achievements in immunology in 2015. He is an active member of the M8 Alliance and co-organizer of the 2017 World Health Summit Regional Meeting in Montreal, Canada. He was elected to the Board of Directors of the Canadian Society for Molecular Biosciences in 2015, Vice president in 2017 and President in 2018. He is serving on the Board of Directors of Research Canada since 2016 and has been appointed member of the College of Reviewers for the Canadian Institutes of Health Research in 2017. Dr. Möröy has been elected fellow of the Canadian Academy of Health Sciences in 2018.
Tarik Möröy obtained his PhD in biochemistry in 1987 from the Ludwig-Maximilians University in Munich (Germany), after conducting his doctoral experimental research at the Institut Pasteur in Paris from 1984 to 1987. From 1988 to 1991, he was a postdoctoral fellow at Columbia University in New York. Upon his return in Germany, he became an assistant professor at the Institut für Molekularbiologie und Tumorforschung of Philipps University in Marburg, where he also obtained his accreditation to supervise academic teaching and research. In 1995, he was promoted to associate professor and, one year later, to full professor in molecular cell biology in the Faculty of Medicine at Duisburg-Essen University. In addition to being a researcher and a professor at the university’s Cellular Biology Institute (Institut für Zellbiologie, IFZ), he also held important administrative duties including that of Executive Director of the IFZ from 1996 to 1999 and again from 2002 to 2005, and Chairman of the Board of the Center for Medical Biotechnology from 2003 to 2005. During this period, he led numerous federally- and European Union-funded research consortia in Germany. He also acted as an evaluator for the Marie Curie training programs, as well as an advisor for the Institut national de la santé et de la recherche médicale (INSERM) and other scientific advisory boards